Rheumatoid arthritis associated with methotrexate-induced pneumonitis: Improvement with i.v. cyclophosphamide therapy
A. Suwa1, M. Hirakata1, S. Satoh1, T. Mimori1, K. Utsumi2, S. Inada3
1Department of Internal Medicine, Keio University School of Medicine; 2Division of Internal Medicine and 3Division of Rheumatic Diseases, Tokyo Metropolitan Ohtsuka Hospital, Tokyo, Japan.
ABSTRACT
Pneumonitis is one of the most serious adverse effects associated with low-dose weekly
methotrexate (MTX) therapy. Immediate cessation of MTX, and the introduction of oxygen
therapy and glucocorticoids usually results in a dramatic improvement in the pulmonary
toxicity. We report here a case of MTX-induced pneumonitis in a patient with rheumatoid
arthritis (RA). Severe hypoxemia and interstitial infiltration in both lung fields did not
respond to the withdrawal of MTX and the administration of oxygen and steroid pulse
therapy. When intravenous cyclophosphamide (CYC) pulse therapy was initiated, however,
rapid physiologic and radiographic improvement was seen. Our case suggests that CYC
treatment may have a beneficial effect on MTX-induced pneumonitis that is resistant to
steroid therapy.
Key words
Cyclophosphamide, interstitial pneumonitis, methotrexate, rheumatoid arthritis.
Please address correspondence and reprint requests to: Akira Suwa, MD, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.
Clin Exp Rheumatol 1999; 17: 355-8.
© Copyright Clinical
and Experimental Rheumatology
1999.